388 related articles for article (PubMed ID: 12123097)
21. Octreotide therapy in carcinoid disease.
Bax ND; Woods HF; Batchelor A; Jennings M
Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
23. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
Gardner-Roehnelt NM
Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
[TBL] [Abstract][Full Text] [Related]
24. Carcinoid tumors--somatostatine in the diagnosis and therapy.
Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J
Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042
[TBL] [Abstract][Full Text] [Related]
25. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
[TBL] [Abstract][Full Text] [Related]
26. Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.
Faiss S; Scherübl H; Riecken EO; Wiedenmann B
Digestion; 1996; 57 Suppl 1():84-5. PubMed ID: 8813478
[TBL] [Abstract][Full Text] [Related]
27. [Somatostatin analogs in the treatment of pancreatic cancer: utopia or feasible alternative?].
Zalatnai A; Pogány V
Orv Hetil; 2000 Oct; 141(43):2333-8. PubMed ID: 11089387
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
29. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
Skinazi F; Zins M; Menu Y; Bernades P; Ruszniewski P
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):673-8. PubMed ID: 8853257
[TBL] [Abstract][Full Text] [Related]
30. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
31. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
[TBL] [Abstract][Full Text] [Related]
33. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
Ruszniewski P; Ducreux M; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Bernades P; Rougier P
Gut; 1996 Aug; 39(2):279-83. PubMed ID: 8977344
[TBL] [Abstract][Full Text] [Related]
34. Treatment of metastatic carcinoid tumours with octreotide.
Ozbey N
Int J Clin Pract; 2002 Jun; 56(5):407. PubMed ID: 12137455
[No Abstract] [Full Text] [Related]
35. [Current treatment of carcinoid tumor].
Elizalde I; Borda F
Gastroenterol Hepatol; 2002 Oct; 25(8):508-13. PubMed ID: 12361534
[No Abstract] [Full Text] [Related]
36. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms.
Ahlman H; Tisell LE
Scand J Gastroenterol; 1987 Oct; 22(8):938-42. PubMed ID: 2891186
[TBL] [Abstract][Full Text] [Related]
37. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analogs in acromegaly.
Freda PU
J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
[No Abstract] [Full Text] [Related]
39. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
40. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
